Neoadjuvant gemcitabine and docetaxel in primary breast angiosarcoma revealed complete pathological remission

Background: Breast angiosarcoma is a rare but aggressive vascular-origin soft tissue tumor. Surgery is the main treatment. However, recent evidence has shown activity of the single agents, paclitaxel or docetaxel, in unresectable or metastasis angiosarcoma.

Objective: To report the case of a patient who received systemic chemotherapy as part of multidisciplinary approach to improve clinical outcome.

Results: We report the case of a 56-year-old female patient who presented with a locally advanced primary angiosarcoma of the left breast and received a combination gemcitabine and docetaxel as neoadjuvant chemotherapy in addition to standard multidisciplinary treatment. The patient was followed for at least 20 months without evidence of disease recurrence.

Conclusion: A perioperative combination chemotherapy consisting of docetaxel and gemcitabine can be considered as a strategy to achieve a pathological complete response and durable remission.